Aarti Drugs Limited has submitted its investor presentation for the second quarter and first half of the fiscal year 2027. The document details significant business and financial highlights, including robust growth in revenue and profitability. The presentation showcases key performance indicators for the respective periods, reflecting the company’s strategic advancements and market position.
Aarti Drugs Unveils Q2 and H1 FY27 Performance
Aarti Drugs Limited has officially released its investor presentation for the second quarter (Q2) and the first half (H1) of the fiscal year 2027. This comprehensive disclosure provides stakeholders with detailed insights into the company’s operational and financial performance during the reported periods.
Key Business and Financial Highlights
The investor presentation includes information on key financial metrics such as Total Revenue, EBITDA & EBITDA Margin, and PAT & PAT Margin for both Q2 and H1 FY27. The company has reported significant year-on-year growth across these parameters, underscoring a period of strong business expansion. For Q2 FY27, Total Revenue saw a +27% increase, with EBITDA & EBITDA Margin growing by +63% and PAT & PAT Margin by +83%. Similarly, H1 FY27 results demonstrate a +23% rise in Total Revenue, a +48% increase in EBITDA & EBITDA Margin, and a +34% jump in PAT & PAT Margin.
Segmental Performance and Strategy
The presentation also breaks down segmental revenue, highlighting the contributions from API, Formulation, and Speciality Chemicals. Therapeutic-wise revenue splits are also provided across various categories like Anti-biotic, Anti-protozoal, and Anti-inflammatory drugs. The company’s strategic focus areas, including manufacturing excellence, R&D, and diversified presence across segments and geographies, are further elaborated upon.
Financial Standing and Outlook
A robust balance sheet is indicated, with strong net operating cash flow generation and low leverage providing financial flexibility. The document further outlines growth strategies focusing on scaling regulated market sales, capacity expansion, and backward integration. The company’s commitment to innovation and its strong R&D thrust are also emphasized, with a significant investment in R&D activities.
Shareholder Value
The company’s approach to rewarding shareholders is also detailed, outlining its distribution policy of distributing ~15% to 30% of consolidated net profits and highlighting significant distributions through dividends and share buybacks over the past seven years.
Source: BSE
